- Volume 15 Issue 17
DOI QR Code
Overcoming 5-Fu Resistance of Colon Cells through Inhibition of Glut1 by the Specific Inhibitor WZB117
- Liu, Wei (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
- Fang, Yong (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
- Wang, Xiao-Tong (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
- Liu, Ju (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
- Dan, Xing (Northeast Pharmaceutical Group Sales Co., Ltd.) ;
- Sun, Lu-Lu (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University)
- Published : 2014.09.15
Background: 5-Fluorouracil (5-FU) is the most commonly used drug in colon cancer therapy. However, despite impressive clinical responses initially, development of drug resistance to 5-Fu in human tumor cells is the primary cause of failure of chemotherapy. In this study, we established a 5-Fu-resistant human colon cancer cell line for comparative chemosensitivity studies. Materials and Methods: Real time PCR and Western blotting were used to determine gene expression levels. Cell viability was measured by MTT assay. Glucose uptake was assess using an Amplex Red Glucose/Glucose Oxidase assay kit. Results: We found that 5-Fu resistance was associated with the overexpression of Glut1 in colon cancer cells. 5-Fu treatment at low toxic concentration induced Glut1 expression. At the same time, upregulation of Glut1 was detected in 5-Fu resistant cells when compared with their parental cells. Importantly, inhibition of Glut1 by a specific inhibitor, WZB117, significantly increased the sensitivity of 5-Fu resistant cells to the drug. Conclusions: This study provides novel information for the future development of targeted therapies for the treatment of chemo-resistant colon cancer patients. In particular it demonstrated that Glut1 inhibitors such as WZB117 may be considered an additional treatment options for patients with 5-Fu resistant colon cancers.
5-Fluorouracil;colon cancer;glut1;specific inhibitor;WZB117
- Carvalho KC, Cunha IW, Rocha RM, et al (2011). GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics, 66, 965-72. https://doi.org/10.1590/S1807-59322011000600008
- Beck A, Etienne MC, Cheradame S, et al (1994). A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer, 30, 1517-22. https://doi.org/10.1016/0959-8049(94)00216-R
- Boyer J, McLean EG, Aroori S, et al (2004). Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res, 10, 2158-67. https://doi.org/10.1158/1078-0432.CCR-03-0362
- Curtin NJ, Harris AL, Aherne GW (1991). Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res, 51, 2346-52.
- DeBraud F, Munzone E, Nole F, et al (1998). Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol, 21, 279-83. https://doi.org/10.1097/00000421-199806000-00015
- Herrmann R (1996). 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol, 7, 551-2. https://doi.org/10.1093/oxfordjournals.annonc.a010668
- Hur H, Xuan Y, Kim YB, et al (2013). Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol, 42, 44-54.
- Li LJ, Li GD, Wei HL, et al (2014). Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells. Asian Pac J Cancer Prev, 15, 3123-8. https://doi.org/10.7314/APJCP.2014.15.7.3123
- Liu Y, Cao Y, Zhang W, et al (2012). A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther, 11, 1672-82. https://doi.org/10.1158/1535-7163.MCT-12-0131
- Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330-8. https://doi.org/10.1038/nrc1074
- Peters GJ, van Triest B, Backus HH, et al (2000). Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer, 36, 916-24. https://doi.org/10.1016/S0959-8049(00)00026-5
- Subbarayan PR, Lee K, Ardalan B (2010). Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. Anticancer Res, 30, 1157-62.
- Vander HM, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33. https://doi.org/10.1126/science.1160809
- Wang FS, Aschele C, Sobrero A, et al (1993). Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res, 53, 3677-80.
- Wang YD, Li SJ, Liao JX (2013). Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat, 12, 525-35.
- Wood TE, Dalili S, Simpson CD, et al (2008). A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther, 7, 3546-55. https://doi.org/10.1158/1535-7163.MCT-08-0569
- Wu CH, Ho YS, Tsai CY, et al (2009). In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int J Cancer, 124, 2210-9. https://doi.org/10.1002/ijc.24189
- Zhang N, Yin Y, Xu SJ, et al (2008). 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 13, 1551-69. https://doi.org/10.3390/molecules13081551
- Zhao Y, Butler EB, Tan M (2013). Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis, 4, 532. https://doi.org/10.1038/cddis.2013.60
- Zhao Y, Liu H, Liu Z, et al (2011). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res, 71, 4585-97. https://doi.org/10.1158/0008-5472.CAN-11-0127
- Zhao L, Wang WJ, Zhang JN, et al (2014). 5-Fluorouracil and Interleukin-2 immunochemotherapy enhances immunogenicity of Non-Small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44. https://doi.org/10.7314/APJCP.2014.15.9.4039
- Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity vol.37, pp.2, 2016, https://doi.org/10.1007/s13277-015-4048-0
- Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation vol.77, pp.5, 2016, https://doi.org/10.1007/s00280-016-3007-9
- gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma vol.12, pp.10, 2017, https://doi.org/10.1080/15592294.2017.1365207
- Brucine Sensitizes HepG2 Human Liver Cancer Cells to 5-fluorouracil via Fas/FasL Apoptotic Pathway vol.13, pp.3, 2017, https://doi.org/10.3923/ijp.2017.323.331
- Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells vol.8, pp.2, 2017, https://doi.org/10.1038/cddis.2017.35
- New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy vol.234, pp.1, 2018, https://doi.org/10.1002/jcp.26917
- Role of metabolism in cancer cell radioresistance and radiosensitization methods vol.37, pp.1, 2018, https://doi.org/10.1186/s13046-018-0758-7